Well Told Grants

Federal grant programs / Department of Health and Human Services

Diabetes, Digestive, and Kidney Diseases Extramural Research (93.847)

Diabetes, Digestive, and Kidney Diseases Extramural Research (Assistance Listing 93.847) is run by the National Institutes of Health, part of the Department of Health and Human Services. It awarded $9.6 billion in 7,877 grants from fiscal 2021 to 2025, about $1.2 million per award on average. 68 funding opportunities are open or forecast now.

The typical award was $874,325. Half of the 7,877 awards fell between $320,055 and $1.8 million, and they ranged from $0 to $99.7 million.

Key findings

What the program funds

(1) To promote extramural basic and clinical biomedical research that improves the understanding of the mechanisms underlying disease and leads to improved preventions, diagnosis, and treatment of diabetes, digestive, and kidney diseases. Programmatic areas within the National Institute of Diabetes and Digestive and Kidney Diseases include diabetes, digestive, endocrine, hematologic, liver, metabolic, nephrologic, nutrition, obesity, and urologic diseases. Specific programs areas of interest include the following: (a) For diabetes, endocrine, and metabolic diseases areas: Fundamental and clinical studies including the etiology, pathogenesis, prevention, diagnosis, treatment and cure of diabetes mellitus and its complications; Normal and abnormal function of the pituitary, thyroid, parathyroid, adrenal, and other hormone secreting glands; Hormonal regulation of bone, adipose tissue, and liver; on fundamental aspects of signal transduction, including the action of hormones, coregulators, and chromatin remodeling proteins; Hormone biosynthesis, secretion, metabolism, and binding; and on hormonal regulation of gene expression and the role(s) of selective receptor modulators as partial agonists or antagonists of hormone action; and Fundamental studies relevant to metabolic disorders including membrane structure, function, and transport phenomena and enzyme biosynthesis; and basic and clinical studies on the etiology, pathogenesis, prevention, and treatment of inherited metabolic disorders (such as cystic fibrosis). (b) For digestive disease and nutrition areas: Genetics and genomics of the GI tract and its diseases; Genetics and genomics of liver/pancreas and diseases; Genetics and genomics of nutrition; genetics and genomics of obesity; Bariatric surgery; Clinical nutrition research; Clinical obesity research; Complications of chronic liver disease; Fatty liver disease; Genetic liver disease; HIV and liver; Cell injury, repair, fibrosis and inflammation in the liver; Liver cancer; Liver transplantation; Pediatric liver disease; Viral hepatitis and infectious diseases; Gastrointestinal and nutrition effects of AIDS; Gastrointestinal mucosal and immunology; Gastrointestinal motility; Basic neurogastroenterology; Gastrointestinal development; Gastrointestinal epithelial biology; Gastrointestinal inflammation; Digestive diseases epidemiology and data systems; Nutritional epidemiology and data systems; Autoimmune liver disease; Bile, Bilirubin and cholestasis; Bioengineering and biotechnology related to digestive diseases, liver, nutrition and obesity; Cell and molecular biology of the liver; Developmental biology and regeneration; Drug-induced liver disease; Gallbladder disease and biliary diseases; Exocrine pancreas biology and diseases; Gastrointestinal neuroendocrinology; Gastrointestinal transport and absorption; Nutrient metabolism; Pediatric clinical obesity; Clinical trials in digestive diseases; Liver clinical trials; Obesity prevention and treatment; and Obesity and eating disorders. (c) For kidney, urologic and hematologic diseases areas: Studies of the development, physiology, and cell biology of the kidney; Pathophysiology of the kidney; Genetics of kidney disorders; Immune mechanisms of kidney disease; Kidney disease as a complication of diabetes; Effects of drugs, nephrotoxins and environmental toxins on the kidney; Mechanisms of kidney injury repair; Improved diagnosis, prevention and treatment of chronic kidney disease and end-stage renal disease; Improved approaches to maintenance dialysis therapies; Basic studies of lower urinary tract cell biology, development, physiology, and pathophysiology; Clinical studies of bladder dysfunction, incontinence, pyelonephritis, interstitial cystitis, benign prostatic hyperplasia, urolithiasis, and vesicoureteral reflux; Development of novel diagnostic tools and improved therapies, including tissue engineering strategies, for urologic disorders;Research on hematopoietic cell differentiation; metabolism of iron overload and deficiency; Structure, biosynthesis and genetic regulation of hemoglobin; as well as Research on the etiology, pathogenesis, and therapeutic modalities for the anemia of inflammation and chronic diseases. (2) To encourage basic and clinical research training and career development of scientists during the early stages of their careers. The Ruth L. Kirschstein National Research Service Award (NRSA) funds basic and clinical research training, support for career development, and the transition from postdoctoral biomedical research training to independent research related to diabetes, digestive, endocrine, hematologic, liver, metabolic, nephrologic, nutrition, obesity, and urologic diseases. (3) To expand and improve the Small Business Innovation Research (SBIR) program. The SBIR Program aims to increase and facilitate private sector commercialization of innovations derived from Federal research and development; to enhance small business participation in Federal research and development; and to foster and encourage participation of socially and economically disadvantaged small business concerns and women-owned small business concerns in technological innovation. (4) To utilize the Small Business Technology Transfer (STTR) program. The STTR Program intends to stimulate and foster scientific and technological innovation through cooperative research and development carried out between small business concerns and research institutions; to foster technology transfer between small business concerns and research institutions; to increase private sector commercialization of innovations derived from Federal research and development; and to foster and encourage participation of socially and economically disadvantaged small business concerns and women-owned small business concerns in technological innovation.

From the federal Assistance Listing. Read the full listing on SAM.gov.

Open opportunities

43 more opportunities are listed with all open grants from Department of Health and Human Services.

Rules from the program listing

Who can apply

Project Grants: Universities, colleges, medical, dental and nursing schools, schools of public health, laboratories, hospitals, State and local health departments, other public or private institutions, both non-profit and for-profit, and individuals who propose to establish, expand, and improve research activities in health sciences and related fields. NRSAs: Support is provided for academic and research training only, in health and health-related areas that are periodically specified by the National Institutes of Health. To be eligible, predoctoral awardees must have completed the baccalaureate degree and postdoctoral awardees must have a professional or scientific degree (M.D., Ph.D., D.D.S., D.O., D.V.M., Sc.D., D.Eng., or equivalent domestic or foreign degree). Individuals must be nominated and sponsored by a public or nonprofit private institution having staff and facilities appropriate to the proposed research training program. All awardees must be citizens or have been admitted to the United States for permanent residence. Nonprofit domestic organizations may apply for the Institutional NRSA.

Continue reading on SAM.gov

What the money can and cannot pay for

Project Grants provide funds for salaries, equipment, supplies, travel, and other expenses associated with scientific investigation relevant to program objectives. NRSAs are made directly to individuals for research training in specified biomedical shortage areas, or, to institutions to enable them to make NRSAs to individuals selected by them. Each individual who receives a NRSA is obligated upon termination of the award to comply with certain service and payback provisions. SBIR Phase I grants (of approximately 6-months duration) are to establish the technical merit and feasibility of a proposed research effort that may lead to a commercial product or process. Phase II grants are for the continuation of the research initiated in Phase I and that are likely to result in commercial products or processes. Only Phase I awardees are eligible to receive Phase II support. STTR Phase I grants (normally of 1-year duration) are to determine the scientific, technical, and commercial merit and feasibility of the proposed cooperative effort that has potential for commercial application. Phase II funding is based on results of research initiated in Phase I and scientific and technical merit and commercial potential of the Phase II application.

Matching requirements

This program has no statutory formula. Matching requirements are not applicable to this assistance listing. MOE requirements are not applicable to this assistance listing.

Deadlines

Contact the headquarters or regional location, as appropriate for application deadlines

Award range and average, in the agency's words

Project Grants: Range of $1,300 to $10,834,000; $418,000 average NRSAs: Range of $2,500 to $869,000; $116,000 average SBIR: Range of $6,500 to $2,074,000; $585,000 average

Quoted from the program's federal Assistance Listing. The notice of funding opportunity is the official source for each competition's rules.

Funding history and past recipients

From fiscal 2021 to 2025, Diabetes, Digestive, and Kidney Diseases Extramural Research (93.847) awarded$9.6 billion across 7,877 grant awards, an average of $1.2 million per award.

Largest recipients, fiscal 2021 to 2025
RecipientStateAwardsAmount
Regents of the University of MichiganMichigan272$344 million
The Trustees of the University of PennsylvaniaPennsylvania188$273 million
University of Pittsburgh - of the Commonwealth System of Higher EducationPennsylvania208$236 million
The Washington UniversityMissouri187$227 million
The Regents of the University of California, San FranciscoCalifornia176$208 million
Yale UnivConnecticut166$207 million
University of South FloridaFlorida17$205 million
The Regents of the University of ColoradoColorado183$204 million
Vanderbilt University Medical CenterTennessee133$200 million
The Trustees of Columbia University in the City of New YorkNew York148$193 million
Icahn School of Medicine at Mount SinaiNew York132$192 million
University of California, San DiegoCalifornia124$190 million
The General Hospital CorporationMassachusetts152$186 million
The Leland Stanford Junior UniversityCalifornia137$170 million
Mayo ClinicMinnesota133$169 million
The Johns Hopkins UniversityMaryland131$160 million
The University of Texas Southwestern Medical CenterTexas131$154 million
University of North Carolina at Chapel HillNorth Carolina113$152 million
Baylor College of MedicineTexas128$141 million
Northwestern UniversityIllinois101$140 million

Top states: California ($1.2 billion), Massachusetts ($932 million), New York ($801 million), Pennsylvania ($763 million), Texas ($483 million), Michigan ($426 million), Florida ($420 million), Illinois ($403 million), North Carolina ($374 million), Ohio ($324 million).

Who usually wins

Colleges and universities received 70% of the money, nonprofits 22% and small businesses 3.8%.

Recipient typeAwardsAmountShare
Colleges and universities5,504$6.7 billion70%
Nonprofits1,627$2.1 billion22%
Other343$383 million4.0%
Small businesses397$366 million3.8%
Businesses2$5.2 millionless than 0.1%
State and local governments4$1.4 millionless than 0.1%

By state

48 states have a page for this program: those that received at least $1 million or 10 awards.

Grants by recipient's state, fiscal 2021 to 2025
StateAwardsAmount
California1,010$1.2 billion
Massachusetts719$932 million
New York652$801 million
Pennsylvania596$763 million
Texas446$483 million
Michigan347$426 million
Florida224$420 million
Illinois301$403 million
North Carolina312$374 million
Ohio249$324 million
Tennessee245$295 million
Minnesota237$291 million
Missouri240$286 million
Connecticut200$252 million
Maryland219$239 million
Washington161$237 million
Colorado237$235 million
Georgia156$157 million
Virginia118$142 million
Indiana144$137 million
Alabama126$132 million
Wisconsin120$111 million
Utah81$89.2 million
Arizona70$88.8 million
South Carolina69$85.3 million
Louisiana63$65.5 million
Iowa52$63.0 million
Oregon51$57.8 million
Kentucky56$57.7 million
New Jersey52$53.7 million
District of Columbia45$52.6 million
Kansas45$42.6 million
Rhode Island47$40.6 million
Oklahoma34$33.6 million
Maine19$29.5 million
Arkansas17$24.0 million
New Hampshire16$18.8 million
Nebraska11$14.9 million
Nevada8$13.4 million
Mississippi9$8.4 million
New Mexico9$8.1 million
Vermont7$7.7 million
Delaware8$7.3 million
North Dakota4$6.1 million
Hawaii5$4.5 million
Montana3$3.4 million
West Virginia4$3.2 million
Wyoming2$2.1 million
Alaska2$820,757
South Dakota2$448,531
Puerto Rico1$150,000

Award amounts are federal obligations reported to USAspending.gov for fiscal 2021 to 2025; see how our data works.